German scientists have linked a rare type of cerebral vein thrombosis and the AstraZeneca coronavirus vaccine. This was reported in a statement by the Paul Ehrlich Institute for Vaccines and Biomedical Medicines, RIA Novosti reports.
Experts have found that the increase in the number of cases of a specific form of thrombosis, which is associated with a decrease in platelet count and bleeding, coincides in time with the vaccination of the British-Swedish company. The statement notes that German researchers have also recorded new cases of complications after vaccinations.
All vaccine data received are currently being reviewed by the European Medicines Agency (EMA).
Earlier, on the recommendation of the Paul Ehrlich Institute, Germany stopped vaccination against coronavirus with the drug AstraZeneca. The authorities came to such a decision after reports of poor health among those who received the vaccine. Spain, France and Italy have also stopped vaccination with this drug.
At the same time, the company announced the safety of the vaccine. AstraZeneca explained that a detailed study of the health status of more than 17 million people vaccinated in the EU and the UK with the coronavirus drug showed no evidence of an increased risk of pulmonary embolism, deep vein thrombosis or thrombocytopenia.
However, nine more European countries have stopped or temporarily limited vaccination with AstraZeneca due to thrombosis in patients who were vaccinated with it. Austria, Estonia, Latvia, Lithuania and Luxembourg have stopped using the drug from a specific batch of one million doses, which was supplied to 17 European countries. At the same time, Denmark, Iceland and Norway have stopped all their supplies of this vaccine.